Cargando…
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer...
Autores principales: | Wei, Qiong, Liu, Haijuan, Zhou, Honghao, Zhang, Dejun, Zhang, Zhiwei, Zhou, Qibing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374574/ https://www.ncbi.nlm.nih.gov/pubmed/25881156 http://dx.doi.org/10.1186/s12885-015-1149-5 |
Ejemplares similares
-
The cytosol activity of thymidine phosphorylase in endometrial cancer
por: Miszczak-Zaborska, Elżbieta, et al.
Publicado: (2008) -
ACQUISITION OF CHICK CYTOSOL THYMIDINE KINASE ACTIVITY BY THYMIDINE KINASE-DEFICIENT MOUSE FIBROBLAST CELLS AFTER FUSION WITH CHICK ERYTHROCYTES
por: Kit, Saul, et al.
Publicado: (1974) -
Pathways of thymidine hypermodification
por: Lee, Yan-Jiun, et al.
Publicado: (2021) -
Synthesis of Thymidine Phosphorylase Inhibitor Based on Quinoxaline Derivatives and Their Molecular Docking Study
por: Almandil, Noor Barak, et al.
Publicado: (2019) -
In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant
por: Yang, Rong, et al.
Publicado: (2021)